A Decade of Innovation

Our commitment to neurology and the people living with these disorders has been unwavering. From helping to manage partial-onset (focal) seizures of epilepsy to supporting those living with Parkinson’s disease (PD), our ingenuity and innovative spirit are what helps us develop novel treatments that address the daily challenges people encounter living with serious neurological conditions.

Parkinson’s disease*

Approximate

10M

Worldwide
Approximate

1M

United States

Epilepsy*

Approximate

50M

Worldwide
Approximate

3.4M

United States

Our Medicines

KYNMOBI® (apomorphine HCl) sublingual film is a prescription medicine used to treat short-term (acute), intermittent “off” episodes in people with Parkinson’s disease (PD).

Please read the full Prescribing Information for KYNMOBI.

For HCP information, please visit: Visit KYNMOBI HCP site

For KYNMOBI information and support, please visit: KYNMOBI KYNNECT

For patient information, please visit: Visit KYNMOBI patient site

Aptiom® (eslicarbazepine acetate) is a prescription medicine to treat partial-onset seizures in patients 4 years of age and older.

Please read the full Prescribing Information for Aptiom.

For HCP information, please visit: Visit Aptiom HCP site

For patient information, please visit: Visit Aptiom patient site

What is
Sunovion Answers?

We believe in putting people first, which is why we created Sunovion Answers. Our caring and skilled team is available to provide knowledge and resources to help patients, caregivers, family members, or providers. We’re committed to finding solutions and connecting people to the information they need.

Specialists are available anytime between 8AM and 12 midnight (ET): 1-855-552-8832

A woman wearing glasses taking notes from her online research.

Our Neurology Pipeline

We strive to develop new treatments to help people living with neurologic disorders manage their symptoms. From supporting patients living with neuropathic pain to more advancements in Parkinson’s disease, we are leading the way to a healthier world.

Therapeutic Area

Candidate

Indication/Target

Phase

 

Neurology

Ulotaront (SEP-363856)

Parkinson’s disease psychosis

Phase 2 50% complete

Neurology

DSP-3905

Neuropathic pain

Phase 1 25% complete

Neurology

SEP-380135

Agitation in Alzheimer’s disease

Phase 1 25% complete

Therapeutic Area

Indication/Target

Candidate

Neurology

Parkinson’s disease psychosis

Ulotaront
(SEP-363856)

Phase 2 50% complete

Neurology

Neuropathic pain

DSP-3905

Phase 1 25% complete

Neurology

Agitation in Alzheimer’s disease

SEP-380135

Phase 1 25% complete